IRVINE, Calif. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced the appointment of Chief Medical Officer Rui Avelar , MD, as Head of Research & Development (“R&D”), effective immediately. Dr.

IRVINE, Calif. , Aug. 15, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS) (“Evolus”) today announced that the underwriters of Evolus’ previously announced public offering that initially closed on July 23, 2018 , have purchased an additional 600,000 shares of Evolus’ common stock at a public

IRVINE, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today reported financial results for the second quarter ended June 30, 2018. Second Quarter 2018 and Recent Highlights: Announced early resubmission to the U.S.

BLA Resubmission to be Formally Filed Today Commercial Launch Planned for Spring 2019 IRVINE, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a company dedicated to aesthetic medicine, announced that today it is resubmitting its Biologics License Application (“BLA”) for its

IRVINE, Calif. , July 26, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a company dedicated to aesthetic medicine, today announced that it will release 2018 second quarter financial results before the market open on Thursday, August 2, 2018 .

IRVINE, Calif. , July 18, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq:EOLS) (“Evolus”) announced today the pricing of its public offering of 4,000,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions.  The offering consists of

IRVINE, Calif. , July 16, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq:EOLS) (“Evolus”) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) and commenced a proposed underwritten public offering of 5,000,000 shares of its

IRVINE, Calif. , June 22, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a company dedicated to aesthetic medicine, today announced the presentation of a comprehensive overview of the clinical program for its neuromodulator product candidate, DWP-450

Mr. Jafar Joins Evolus from Allergan as the Company Expands its Commercial Infrastructure IRVINE, Calif. , June 18, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS) (“Evolus” or the “Company”), a company dedicated to aesthetic medicine, today announced the expansion of its management team with

IRVINE, Calif. , June 14, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (“Evolus”) (NASDAQ:EOLS), a premiere aesthetics company, announced today that members of management will be participating in two upcoming investor conferences in New York, NY .                   Event:   Cantor 2018 Dermatology &